Rocket Pharmaceuticals is trading 10.06% higher at $2.79 after Goldman Sachs upgraded its rating from Sell to Neutral and raised its price target from $3 to $4. - The revised view followed updated RP-A501 Danon disease data, including long-term Phase 1 activity and preliminary observations from Phase 2 patients. - The pivotal trial timeline remains extended, with results expected in 2028.